On March 18, 2019 Salarius Pharmaceuticals, LLC, a clinical-stage oncology company targeting the epigenetic causes of cancers, reported that its Chief Executive Officer David Arthur will present at the 29th Annual Oppenheimer Healthcare Conference held March 19-20, 2019, at the Westin New York Grand Central Hotel (Press release, Salarius Pharmaceuticals, MAR 18, 2019, View Source [SID1234534475]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Arthur will present an overview of Salarius’ business, including its development strategy for its lead compound, Seclidemstat, which targets the epigenetic dysregulation underlying Ewing sarcoma, a devastating pediatric, adolescent and young adult bone cancer for which no targeted therapies currently exist. Salarius is currently enrolling patients in an open-label Phase 1 dose escalation/dose expansion study, which is expected to conclude in 2020.

Details of Salarius’ presentation are as follows:

Event:

29th Annual Oppenheimer Healthcare Conference

Date:

Wednesday, March 20, 2019

Time:

11:30 a.m. (Eastern Time)

Location:

Westin New York Grand Central; Track 2

An audio webcast will be accessible via the News and Events section of the Salarius Pharmaceuticals website: View Source An archive of the audio will remain available for 90 days following the presentation.